Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Triple Negative Breast Cancers”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT02685657
What this trial is testing

Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Russian Academy of Medical Sciences 164
Early research (Phase 1)Ended earlyNCT04691375
What this trial is testing

PY314 in Subjects With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorGynecologic CancerBreast Cancer+6 more
Ikena Oncology 86
Early research (Phase 1)Looking for participantsNCT07623369
What this trial is testing

A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors

Who this might be right for
Solid TumorNon-small Cell Lung CancerHepatocellular Carcinoma+9 more
Huahui Health 299
Early research (Phase 1)Looking for participantsNCT07137416
What this trial is testing

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast Carcinoma+13 more
National Cancer Institute (NCI) 36
Early research (Phase 1)Ended earlyNCT03742349
What this trial is testing

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

Who this might be right for
Triple Negative Breast Cancer (TNBC)
Novartis Pharmaceuticals 64
Large-scale testing (Phase 3)Study completedNCT04799249
What this trial is testing

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

Who this might be right for
TNBC - Triple-Negative Breast CancerBreast Cancer
G1 Therapeutics, Inc. 194
Not applicableActive Not RecruitingNCT07821229
What this trial is testing

Combination of Mitomycin and Carboplatin in Neoadjuvant Therapy in BRCA-associated Triple-negative Locally Advanced Breast Cancer

Who this might be right for
Breast Cancer (Early Breast Cancer)BRCA 1 Gene MutationBRCA 2 Gene Mutation
N.N. Petrov National Medical Research Center of Oncology 30
Testing effectiveness (Phase 2)Study completedNCT03254654
What this trial is testing

Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer

Who this might be right for
Advanced Triple-Negative Breast Cancer
Fudan University 66
Testing effectiveness (Phase 2)Ended earlyNCT04916002
What this trial is testing

A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

Who this might be right for
Merkel Cell CarcinomaCutaneous Squamous Cell CarcinomaBasal Cell Carcinoma+3 more
Regeneron Pharmaceuticals 77
Early research (Phase 1)Study completedNCT03000257
What this trial is testing

Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
AbbVie 182
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07299409
What this trial is testing

First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.

Who this might be right for
Advanced Triple Negative Breast CancerBreast Cancer MetastaticBreast Cancer
Nathalie Levasseur 24
Testing effectiveness (Phase 2)Looking for participantsNCT06851299
What this trial is testing

The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer.

Who this might be right for
Metastatic Triple-negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 60
Early research (Phase 1)Ended earlyNCT01930292
What this trial is testing

Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies

Who this might be right for
Solid Tumors
Debiopharm International SA 31
Testing effectiveness (Phase 2)Ended earlyNCT04927884
What this trial is testing

Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies

Who this might be right for
Advanced Triple Negative Breast Cancer
ImmunityBio, Inc. 3
Early research (Phase 1)Study completedNCT00998036
What this trial is testing

Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors

Who this might be right for
Triple Negative Breast Cancer
Columbia University 9
Early research (Phase 1)Study completedNCT06894771
What this trial is testing

MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)

Who this might be right for
Malignant Neoplasm
Merck Sharp & Dohme LLC 5
Early research (Phase 1)Study completedNCT03752398
What this trial is testing

XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

Who this might be right for
Melanoma (Excluding Uveal Melanoma)Cervical CarcinomaPancreatic Carcinoma+13 more
Xencor, Inc. 198
Early research (Phase 1)Study completedNCT02259114
What this trial is testing

A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)

Who this might be right for
NUT Midline CarcinomaTriple Negative Breast CancerNon-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation+3 more
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 47
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07487519
What this trial is testing

Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.

Who this might be right for
Breast Cancer (Triple Negative Breast Cancer (TNBC))
Shanghai Henlius Biotech 180
Not applicableLooking for participantsNCT06431100
What this trial is testing

A Single-arm, Single-center, Open Clinical Study

Who this might be right for
Gastric CancerEsophageal CancerCervical Cancer+2 more
Beijing Geekgene Technology Co., LTD 10
Next Page